(Q35534163)

8 August 2017

title

Treatment pathways, resource use and costs in the management of small cell lung cancer (English)

1 reference

8 August 2017

1 reference

Oliver E

1

1 reference

8 August 2017

Killen J

2

1 reference

8 August 2017

Kiebert G

3

1 reference

8 August 2017

Hutton J

4

1 reference

8 August 2017

Hall R

5

1 reference

8 August 2017

Higgins B

6

1 reference

8 August 2017

Bourke S

7

1 reference

8 August 2017

Paschen B

8

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

8 August 2017

1 reference

8 August 2017

volume

56

1 reference

8 August 2017

issue

10

1 reference

8 August 2017

page(s)

785-790

1 reference

Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1745921

Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1745921

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1745921

Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1745921

The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1745921

Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1745921

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1745921

Small cell lung cancer: staging with MR imaging.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1745921

The cost of treating small cell lung cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1745921

Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1745921

Counting the costs of cancer therapy

26 September 2018

1 reference

12 December 2020

Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer

1 reference

12 December 2020

Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer

1 reference

12 December 2020

Cost-effectiveness analysis of somatostatin receptor scintigraphy

1 reference

12 December 2020

A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer

1 reference

12 December 2020

Identifiers

DOI

10.1136/THORAX.56.10.785

1 reference

8 August 2017

1 reference

8 August 2017

1 reference